Genome Balance Sheet Health
Financial Health criteria checks 5/6
Genome has a total shareholder equity of ₩112.5B and total debt of ₩23.2B, which brings its debt-to-equity ratio to 20.6%. Its total assets and total liabilities are ₩158.2B and ₩45.7B respectively.
Key information
20.6%
Debt to equity ratio
₩23.19b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩84.38b |
| Equity | ₩112.49b |
| Total liabilities | ₩45.71b |
| Total assets | ₩158.20b |
Recent financial health updates
Is Genome (KOSDAQ:314130) A Risky Investment?
Jul 03
Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?
Mar 08Genome (KOSDAQ:314130) Is In A Good Position To Deliver On Growth Plans
Mar 17Recent updates
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump
Sep 06Is Genome (KOSDAQ:314130) A Risky Investment?
Jul 03Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump
May 27Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump
Apr 11Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?
Mar 08Genome (KOSDAQ:314130) Is In A Good Position To Deliver On Growth Plans
Mar 17Financial Position Analysis
Short Term Liabilities: A314130's short term assets (₩93.5B) exceed its short term liabilities (₩24.9B).
Long Term Liabilities: A314130's short term assets (₩93.5B) exceed its long term liabilities (₩20.8B).
Debt to Equity History and Analysis
Debt Level: A314130 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A314130's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A314130 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A314130 has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 25.1% each year.